



April 22, 2008

**TO WHO IT MAY CONCERN**

**RE: OXYSURE SYSTEMS, INC.**

OxySure<sup>®</sup> was admitted to the NTEC Medical Technology accelerator in early 2004 after successfully passing through NTEC's due diligence process. This process included a review of the company's business, scientific and intellectual property claims (including freedom to operate) by medical device industry veterans, scientists, physicians and NTEC legal counsel. NTEC accepts into our support program less than 4% of all applicants. Our business review of the company indicated a need for improved oxygen delivery in a variety of substantial and diverse industry segments. Further, this research indicated existing customer pain that was not being addressed by current solutions as well as an untapped opportunity to expand select markets.

NTEC worked with the OxySure<sup>®</sup> technical team to complete third party validation testing of their core, oxygen-generating technology which confirmed the company's claims regarding their ability to deliver medically pure oxygen in large quantities over a period of time. In our assessment, this ability to create a product that could generate oxygen on-demand, rapidly and without heat or hazardous waste, would allow the company to enter the consumer market as both a displacement and expansion product. We also found interest and opportunity for the OxySure<sup>®</sup> product platform in commercial markets such as emergency services, mining, education, government and competitive sports...all of which benefit from a safe, reliable and cost-effective emergency oxygen solution.

Fast forward just over 30 months. The company had completed their fully functioning, pre-manufacturing, test units, built an experienced team and completed the FDA product clearance process. At this time, it became clear that OxySure<sup>®</sup> had attained the key business and technical milestones mutually agreed to with NTEC. As a result, OxySure<sup>®</sup> became the first company to graduate from NTEC and the first to move into their own, specially designed lease space. Looking ahead, I believe OxySure<sup>®</sup> will continue to take market share, in their target markets, from existing competitors because of their superior product and ability to execute. As their volumes grow, the company will gain cost and pricing advantages over their competitors, further expanding their revenue base. OxySure<sup>®</sup> is putting in place the human resources needed to scale the company and continue development of their oxygen on-demand platform. I believe with increased product visibility and continued product development, the OxySure<sup>®</sup> platform will see rapid short-term and sustainable long-term revenue growth.

Respectfully,

A handwritten signature in black ink that reads 'Larry W. Calton'. The signature is written in a cursive style.

Larry W. Calton  
Executive Director  
NTEC, Inc.